Table 1

Clinical data and antiganglioside antibody detection in the 29 patients with peripheral neuropathy and cancer

Patient	Sex	Age (years)	Delay (months)*	Evolution	Type	Tumour	Anti-GM1 reactivity	Immunodot-blot titre	ELISA titre	Other reactivity (immunodot-blot)
*Positive number indicates that the neuropathy preceded the cancer diagnosis and negative number that the neuropathy followed the diagnosis of cancer. In all the cases the neuropathy and the cancer were simultaneously present at least at one time.
†Perivascular inflammatory infiltrates on nerve biopsy.
A, acute; C, chronic; CIDP, chronic inflammatory demyelinating polyneuropathy; DASMN, distal axonal sensory/sensorimotor neuropathy; F, female; GBS, Guillain–Barré syndrome; M, male; SA, subacute; SSN, subacute sensory neuropathy; SCLC, small cell lung cancer.
1	M	72	−36	C	DASMN	Urinary	0
2	M	85	−9	C	DASMN	Lung (non-SCLC)	0
3	M	63	−24	C	DASMN	Lung (SCLC)	0
4	M	39	+0.5	A	DASMN	Thyroid	0
5	M	77	−1	A	Plexopathy	Thymus	0
6	M	73	−26	C	SSN	Lung (SCLC)	0
7	M	78	−2	SA	Axonal and demyelinating	Prostate	0
8	M	65	+0.5	SA	Asymmetrical axonal neuropathy†	Tongue	+	1/100	2
9	M	51	−2	SA	DASMN	Metastatic adenocarcinoma	+	1/100	2
10	F	59	−7	A	SSN	PET mediastinal fixation	0
11	M	61	−6	C	CIDP	Liver	+	1/500	7.1	GM2 (1/100)
12	M	84	−7	SA	Asymmetrical axonal neuropathy	Lung	+	1/200	3.9
13	M	74	−4	C	Asymmetrical axonal neuropathy†	Urinary	+	1/200	3.3	GM3 (1/200)
14	M	61	−1	A	DASMN	Stomach	0
15	F	66	−36	SA	CIDP	Malignant lymphoma	0
16	F	73	−26	C	DASMN	Pancreas	+	1/200	2.2
17	M	75	−24	C	DASMN	Kidney	+	1/500	10	GD1b (1/100)
18	M	73	−3	SA	CIDP	Pancreas	0
19	M	75	+2	SA	DASMN	Tonsil	0
20	M	57	−12	SA	SSN	Lung	0
21	M	48	−3	SA	Demyelinating neuropathy	Melanoma	0
22	M	73	−4	C	CIDP	Colon	+	1/200	6
23	M	65	−3	SA	SSN	Lung	0
24	M	70	+3	C	DASMN	Malignant lymphoma	0
25	M	72	+22	C	DASMN	Malignant lymphoma	+	1/500	5.9
26	M	73	+0.5	SA	Axonal and demyelinating	Colon	0
27	M	66	−1	A	GBS	Colon	0
28	M	65	−18	C	Asymmetrical neuropathy†	Malignant lymphoma	0
29	M	54	−0.5	A	GBS	Tongue	0